Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis

Abstract

Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.

1. A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
       2. A pharmaceutical composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       3. The pharmaceutical composition of  claim 2 , packaged and identified for use in the treatment of at least one disorder selected from the group consisting of atherosclerosis, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis, in-stent-stenosis, rheumatoid arthritis, juvenile rheumatoid arthritis and inflammatory bowl disease in a subject in need thereof. 
     
     
       4. The pharmaceutical composition of  claim 3 , further comprising at least one additional compound. 
     
     
       5. The pharmaceutical composition of  claim 4 , wherein said additional compound is selected from the group consisting of HMGCoA reductase inhibitors (statins), mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens. 
     
     
       6. A method of treatment of a disorder selected from the group consisting of atherosclerosis, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and in-stent-stenosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of the compound of  claim 1 . 
     
     
       7. The method of  claim 6 , wherein administration of said compound is mucosal, nasal, oral or intraperitoneal administration. 
     
     
       8. The method of  claim 6 , wherein said compound is administered in addition to a therapeutically effective amount of at least one additional compound. 
     
     
       9. The method of  claim 8 , wherein said additional compound is selected from the group consisting of HMGCoA reductase inhibitors (statins), mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens. 
     
     
       10. A method of treatment of a disorder selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis and inflammatory bowl disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of the compound of  claim 1 . 
     
     
       11. The method of  claim 10 , wherein said compound is administered via mucosal, nasal, oral or intraperitoneal administration. 
     
     
       12. The method of  claim 10 , wherein said compound is administered in addition to a therapeutically effective amount of at least one additional compound. 
     
     
       13. The method of  claim 12 , wherein said additional compound is selected from the group consisting of HMGCoA reductase inhibitors (statins), mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens.